I've not had any9 Mar 2023 12:33
Hello good folks,
I've decided today to join you all as a shareholder in Valirx. There seems to be a lot of negativity here and looking at the history of the company you have my sympathy. The shareholders have really been put through the ringer here.
It looks like you have some great products VAL201, and VAL301 but these seem to now have lost their shine. I don't think it helps when the BoD refers to them as legacy products.
I've bought into Valerix for CLX001 and I'm surprised that a lot of people still seem to be concentrating on legacy products when this could be the company maker.
This is from the case study:
"The project was evaluated to confirm the impact of the peptide drug candidate against triple negative breast cancer. Over nine months, ValiRx investigated the candidate peptide with a battery of in vitro and in vivo tests. In July 2022, it concluded there was good evidence of biological activity and a strong rationale for further development. In addition to triple negative breast cancer, the tests illustrated promising data against ovarian cancer cells, with the novel mechanism of action potentially allowing further expansion into other hard to treat cancer types.
Cytolytix is now moving onto the next step of its preclinical testing and evaluation, with the aim of preparing the drug candidate for early-stage clinical trials."
There is a lot of anger on the board and I say this in the nicest way coming on a board and venting doesn't really help anyone including yourself. Life is too short for such nonsense. If you no longer believe in the company then just sell up and move on.